Cargando…

Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review

The therapeutic regimen for small cell lung cancer (SCLC) has changed little in the past several decades. Apatinib is a small molecule inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase. Apatinib has demonstrated efficacy against advanced gastric cancer and breast cancer, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Ying-ying, Chen, Tao, Shen, Dan, Zhang, Wei-yun, Wang, Chang-guo, Jiang, Jun-hong, Zeng, Da-xiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783257/ https://www.ncbi.nlm.nih.gov/pubmed/31847652 http://dx.doi.org/10.1177/0300060519887276

Ejemplares similares

Apatinib monotherapy for advanced non‐small cell lung cancer after the failure of chemotherapy or other targeted therapy
por: Liu, Zui, et al.
Publicado: (2018)

Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study
por: Wang, Fen, et al.
Publicado: (2020)

Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma
por: Gao, Shen, et al.
Publicado: (2022)

Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer: A case report
por: Liu, Jin, et al.
Publicado: (2019)

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients
por: Pan, Dengdeng, et al.
Publicado: (2022)

Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study
por: Lin, Haimin, et al.
Publicado: (2019)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
por: Gong, Taojun, et al.
Publicado: (2022)

Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report
por: Jin, Jun, et al.
Publicado: (2019)

Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
por: Zeng, Da-xiong, et al.
Publicado: (2017)

Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series
por: Zhang, Honghong, et al.
Publicado: (2017)

Safety and efficacy of apatinib combined with iodine-125 in chemotherapy-refractory advanced lung cancer: A case report
por: Zhang, Yunchao, et al.
Publicado: (2020)

Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases
por: Xu, Jianping, et al.
Publicado: (2020)

Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study
por: Guo, Yesong, et al.
Publicado: (2019)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study
por: Geng, Qian, et al.
Publicado: (2020)

Efficacy and safety of apatinib monotherapy for patients with advanced breast cancer: a systematic review and meta-analysis
por: Huang, Xuchen, et al.
Publicado: (2022)

Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study
por: Zhu, Anjie, et al.
Publicado: (2019)

Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study
por: Xiao, Yan, et al.
Publicado: (2019)

Effective treatment of apatinib for chemotherapy-refractory advanced gastric carcinoma with AFP-secretion and HER2-positivity: A case report
por: Ding, Xinjing, et al.
Publicado: (2021)

Apatinib for treating advanced intrahepatic cholangiocarcinoma after failed chemotherapy: A case report and literature review
por: Wang, Li-Ye, et al.
Publicado: (2018)

Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer
por: Cui, Yu-jie, et al.
Publicado: (2021)

Efficacy and Safety of Apatinib in the Treatment of Chemotherapy-Refractory Metastatic Colorectal Cancer: A Systematic Review
por: Khan, Aujala Irfan, et al.
Publicado: (2022)

Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib’s Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion
por: Zhao, Lingying, et al.
Publicado: (2022)

Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib
por: Fang, Shen-Cun, et al.
Publicado: (2019)

Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma
por: Zhou, Na, et al.
Publicado: (2016)

Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report
por: Li, Ting, et al.
Publicado: (2019)

Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC
por: Zhou, Peng-zhe, et al.
Publicado: (2021)

Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review
por: Jiang, Dingyi, et al.
Publicado: (2020)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022)

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
por: Yuan, Shumin, et al.
Publicado: (2022)

Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review
por: Zhang, Di, et al.
Publicado: (2019)

A Phase II Study of Apatinib in Patients with Chemotherapy‐Refractory Esophageal Squamous Cell Carcinoma (ESO‐Shanghai 11)
por: Chu, Li, et al.
Publicado: (2021)

Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma
por: Zeng, Da-Xiong, et al.
Publicado: (2017)

Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study
por: Wang, Chunjing, et al.
Publicado: (2023)

The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study
por: Sun, Feifei, et al.
Publicado: (2020)

Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer
por: Su, Meng, et al.
Publicado: (2019)

Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review
por: Yang, Dexiang, et al.
Publicado: (2018)

Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies
por: Li, Haosheng, et al.
Publicado: (2022)

S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020)

Salvage treatment with apatinib for advanced non-small-cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rgqakhu17mo7epemnt0np8nbqp